NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

iclight,

Here are the enrollment numbers of the phase 3 CheckMate 498 study:

Patients enrolled (N = 3034)
Patients not randomized (n = 2474)
• No longer met inclusion criteria (n = 1250)a
• Administrative reason by sponsor (n = 766)a
• Withdrew consent (n = 238)
• Other (n = 198)
• Adverse event (n = 11)
• Poor/noncompliance (n = 6)
• Not reported (n = 3)
• Death (n = 2)

Randomized 1:1

Nivolumab plus radiotherapy (n = 280)
• Received allocated intervention (n = 278)

Temozolomide plus radiotherapy (n = 280)
• Received allocated intervention (n = 275)

Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter: An International Randomized Phase 3 Trial.

Antonio Omuro, MD, Alba A Brandes, MD, Antoine F Carpentier, MD, Ahmed Idbaih, MD, David A Reardon, MD, Timothy Cloughesy, MD, Ashley Sumrall, MD, Joachim Baehring, MD, Martin van den Bent, MD, Oliver Bähr, MD,
Giuseppe Lombardi, MD, Paul Mulholland, FRCP, Ghazaleh Tabatabai, MD, Ulrik Lassen, MD, Juan Manuel Sepulveda, MD, Mustafa Khasraw, MD, Elodie Vauleon, MD, Yoshihiro Muragaki, MD, Anna Maria Di Giacomo, MD, Nicholas Butowski, MD, Patrick Roth, MD, Xiaozhong Qian, PhD, Alex Z Fu, PhD, Yanfang Liu, MD, Von Potter, MD, Alexandros-Georgios Chalamandaris, PhD, Kay Tatsuoka, PhD, Michael Lim, MD, Michael Weller, MD

Published: April 14, 2022

https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noac099/6568419